The “OA-BIO” European consortium

The development of 4P004 is part of the EUREKA - Eurostars Horizon 2020 European research framework program.

Together with its three European partners (the Faculty of Veterinary Medicine of Utrecht University, Chondrometrics GmbH and AO Research Institute Davos), 4Moving Biotech is putting together forces in order to move forward 4P004 up to phase II clinical trial through a biomarker-driven approach.

OA-BIO approach

“OA-BIO" represents the breakthrough development of two components that address an unmet need in advancing OA treatment : therapy and biomarkers.
Our partners are both industrial and academic experts:

AO Research Institute Davos

Prof. Mauro Alini’s research group from AO Research Institute Davos (Switzerland) focuses on cartilage, bone and intervertebral disc tissue engineering and regenerative medicine. ARI has been involved on biomarkers research within the last years and has identified several ones, potentially related with intervertebral disc OA and low back pain.

As part of OA-BIO project, ARI will validate the new liquid biopsy biomarkers predictive for knee OA treatment response.

Chondrometrics

Chondrometrics GmbH (Germany) is a leading provider of quality-controlled, quantitative medical image analysis services for osteoarthritis researchers and the pharmaceutical industry with a strong focus on articular cartilage, meniscus, and muscle from magnetic resonance images (MRI).

Within the OA-BIO project, Chondrometrics will focus on development and qualification of innovative osteoarthritis imaging biomarkers.

Utrecht University

Prof. Marianna Tryfonidou’s research group from Utrecht University (The Netherlands), the leading veterinary medicine faculty in Europe, will validate 4P004 efficacy as a DMOAD for veterinary indication.

4Moving Biotech

4Moving Biotech has previously achieved 4P004 preclinical proof-of-concept and demonstrated its disease modifying properties in OA.

As part of OA-BIO project, ARI will validate the new liquid biopsy biomarkers predictive for knee OA treatment response.

Eurostars funding

OA-BIO consortium has been awarded funding through the highly competitive EUREKA-Eurostars Horizon 2020 program to develop its project over a 3-year period. Eurostars is a funding and support program aiming to help international innovative projects led by R&D-performing small- and medium-sized enterprises (SMEs) that are interested in international collaboration.

Picture of Francis Berenbaum, Co-founder, Chief Executive Officer & Chief Medical Officer

“OA-BIO Eurostars grant represents a unique opportunity to bring together some of the most renowned European teams in the field of OA biomarkers. Our complementarity will undoubtedly lead to results that will not only benefit 4P004 but also the entire scientific community and patients.“

Prof. Francis Berenbaum, CEO/CMO of 4Moving Biotech, Head of rheumatology department at Saint-Antoine Hospital (AP-HP), Professor at Sorbonne University (Paris, France) and Director of a research team at INSERM CRSA.

EU Consortium